These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

997 related articles for article (PubMed ID: 33927718)

  • 1. Repurposing Immunomodulatory Drugs to Combat Tuberculosis.
    Fatima S; Bhaskar A; Dwivedi VP
    Front Immunol; 2021; 12():645485. PubMed ID: 33927718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.
    Adeniji AA; Knoll KE; Loots DT
    Appl Microbiol Biotechnol; 2020 Jul; 104(13):5633-5662. PubMed ID: 32372202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
    Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allicin enhances antimicrobial activity of macrophages during Mycobacterium tuberculosis infection.
    Dwivedi VP; Bhattacharya D; Singh M; Bhaskar A; Kumar S; Fatima S; Sobia P; Kaer LV; Das G
    J Ethnopharmacol; 2019 Oct; 243():111634. PubMed ID: 30537531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential role of adjuvant drugs on efficacy of first line oral antitubercular therapy: Drug repurposing.
    Mishra R; Krishan S; Siddiqui AN; Kapur P; Khayyam KU; Sharma M
    Tuberculosis (Edinb); 2020 Jan; 120():101902. PubMed ID: 32090863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repurposed drug candidates for antituberculosis therapy.
    An Q; Li C; Chen Y; Deng Y; Yang T; Luo Y
    Eur J Med Chem; 2020 Apr; 192():112175. PubMed ID: 32126450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in immunomodulatory strategies for host-directed therapies in combating tuberculosis.
    Ayodele S; Kumar P; van Eyk A; Choonara YE
    Biomed Pharmacother; 2023 Jun; 162():114588. PubMed ID: 36989709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to Combat Multi-Drug Resistance in Tuberculosis.
    Singh V; Chibale K
    Acc Chem Res; 2021 May; 54(10):2361-2376. PubMed ID: 33886255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposing Tamoxifen as Potential Host-Directed Therapeutic for Tuberculosis.
    Boland R; Heemskerk MT; Forn-Cuní G; Korbee CJ; Walburg KV; Esselink JJ; Carvalho Dos Santos C; de Waal AM; van der Hoeven DCM; van der Sar E; de Ries AS; Xie J; Spaink HP; van der Vaart M; Haks MC; Meijer AH; Ottenhoff THM
    mBio; 2023 Feb; 14(1):e0302422. PubMed ID: 36475748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis.
    Abreu R; Giri P; Quinn F
    Front Immunol; 2020; 11():1553. PubMed ID: 32849525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin: Candidate host-directed therapy for tuberculosis in diabetes and non-diabetes patients.
    Restrepo BI
    Tuberculosis (Edinb); 2016 Dec; 101S():S69-S72. PubMed ID: 27720378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Not Available].
    Tiberi S; Buchanan R; Caminero JA; Centis R; Arbex MA; Salazar M; Potter J; Migliori GB
    Presse Med; 2017 Mar; 46(2 Pt 2):e41-e51. PubMed ID: 28256383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of isoprinosine to be repurposed as an adjunct anti-tuberculosis chemotherapy.
    Mishra AK; Yabaji SM; Dubey RK
    Med Hypotheses; 2018 Jun; 115():77-80. PubMed ID: 29685203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The resumption of consumption -- a review on tuberculosis.
    Ducati RG; Ruffino-Netto A; Basso LA; Santos DS
    Mem Inst Oswaldo Cruz; 2006 Nov; 101(7):697-714. PubMed ID: 17160276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China.
    He W; Liu C; Liu D; Ma A; Song Y; He P; Bao J; Li Y; Zhao B; Fan J; Cheng Q; Zhao Y
    J Glob Antimicrob Resist; 2021 Sep; 26():241-248. PubMed ID: 34214699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repurposing-a ray of hope in tackling extensively drug resistance in tuberculosis.
    Maitra A; Bates S; Kolvekar T; Devarajan PV; Guzman JD; Bhakta S
    Int J Infect Dis; 2015 Mar; 32():50-5. PubMed ID: 25809756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs.
    Maitra A; Bates S; Shaik M; Evangelopoulos D; Abubakar I; McHugh TD; Lipman M; Bhakta S
    Br Med Bull; 2016 Jun; 118(1):138-48. PubMed ID: 27151954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.